Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data
Sandro Feriozzi,Cristina Chimenti,Ricardo Reisin
DOI: https://doi.org/10.2147/dddt.s365885
IF: 4.3188
2024-04-04
Drug Design Development and Therapy
Abstract:Sandro Feriozzi, 1 Cristina Chimenti, 2 Ricardo Claudio Reisin 3 1 Department of Nephrology and Dialysis Unit, Belcolle Hospital Viterbo, Italy; 2 Department of Clinical Sciences, Internal Medicine, Anesthesiology and Cardiovascular Sciences, La Sapienza University, Rome, Italy; 3 Department of Neurology, Hospital Británico, Buenos Aires, Argentina Correspondence: Sandro Feriozzi, Nephrology and Dialysis Unit, Belcolle Hospital, Strada Sammartinese snc, Viterbo, 01100, Italy, Tel +39/0761338602, Fax +39/076133600, Email The clinical use of agalsidase alfa as enzyme replacement therapy (ERT) for Fabry disease (FD) has spread since 2001, and a large body of evidence of its effectiveness has been collected. This review presents the clinical and laboratory results achieved with agalsidase alfa, which has been published in the literature. Agalsidase alfa infusion slows down or stops the progression of renal damage, expressed by reduction or stabilization of the annual decline of the glomerular filtration rate; yearly decrease of glomerular filtration rate (slope) sometimes is reduced until its stabilization. ERT prevents or reduces the occurrence of hypertrophic cardiomyopathy or slows the increase over time if it is already present. Moreover, regarding neurological manifestations, ERT improves neuropathic pain and quality of life, and recent data indicated that it may also prevent the burden of cerebrovascular disease. In addition to ERT's clinical benefits, crucial topics like the most appropriate time to start therapy and the role of anti-drug antibodies (ADA) are analyzed. Treatment with agalsidase alfa in patients with FD substantially improves their outcomes and enhances their quality of life in patients with FD. Keywords: Fabry disease, agalsidase alfa, enzyme replacement therapy, clinical outcome in Fabry treated patients Fabry disease (FD) is a genetically X-linked inherited disease due to mutations of the GLA gene encoding for the enzyme α-galactosidase A. Its deficiency determines a progressive deposition of glycosphingolipids such as globotriaosylceramide (Gb3) and its derivate globotriaosylsphingosine (Lyso-Gb3) within the lysosomes with subsequent cellular functional derangements. The disorder is a multisystemic disease that, without treatment, progressively affects the heart, the kidney and the brain, leading to severe complications, including early death. Fabry is a systemic disease; however, the involvement of the kidney, heart, and nervous system leads to the main clinical outcomes. 1 Clinically, we describe the patients according to their gender and type of mutation. Classical mutation has very low or no serum enzyme activity. It is associated in males with severe clinical features and reduced life expectancies due to kidney, heart, or nervous system involvement. The disease appears less severe later in life in females with classical mutation. The nonclassical mutation, called late-onset phenotype, causes very variable clinical features from minimal to severe illness. Often, the involvement is limited to a single organ (cardiac-variant, for example). 2 Enzyme replacement therapy (ERT) has been available for more than twenty years, and it has undoubtedly changed the outcome of the disease. Other therapeutic choices have been available recently, such as a chaperone and the modified enzyme (pegylated), and clinical gene therapy clinical trials are currently being performed. However, the experience with these options is more limited and beyond the aims of this review. 3 Two enzymes are available for therapy, requiring an intravenous infusion every other week. An enzyme of human cell-line origin, agalsidase alfa, is given at 0.2 mg/kg/body weight. The second is agalsidase beta, which originates from Chinese hamster ovary cells and is given 1 mg/kg/body weight. The agalsidase alfa has not been approved by the US Food and Drugs Administration but is available in other countries. 4 This review analyses or summarizes the published studies with agalsidase alfa and adds the authors' real-life experience with this ERT. It must be underlined that studies that support the efficacy of agalsidase beta in FD were also published. ERT in FD aims to prevent or significantly slow down organ involvement by Gb3 deposition. ERT with agalsidase alfa has been available for human therapy since 2001. A registry called Fabry Outcome Survey (FOS) was used to collect data from FD patients worldwide (4500 patients, 26 Countries, 142 sites). It was the primary source for monitoring and disseminating the clinical experiences on the effectiveness of agalsidase alfa. 5,6 We searched the websites PubMed, Scopus, and Web of Science for published articles from January 2001 to December 2023 using the words Fabry enz -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal